Anders Hinsby News Today

Published: Jul 09, 2021 By Brandon May Muna Therapeutics, a private Denmark- and Belgium-based biopharmaceutical company founded in 2020, officially closed a $73 million Series A financing round. The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases. The Series A financing was led by Novo Holdings in conjunction with Sofinnova Partners, DROIA Ventures and LSP Dementia Fund. Additional investors who join...

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases - Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB - Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation - Innovative drug discovery platform leveraging insights from novel targets and pa...

Novo Holdings Launches Muna Therapeutics with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases - Novo Holdings created and built Muna Therapeutics with pioneers in the field of neurodegeneration - Led by an experienced management team of Entrepreneurs-in-Residence from Novo Seeds - Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventu...